|
Synonyms: I5-NP | I5NP | QPI-1002
Compound class:
Nucleic acid
Comment: Teprasiran (I5NP, QPI-1002) is a small interfering RNA (siRNA) that is designed to target p53 (TP53) mRNA [1]. Some of the nucleotides are chemically modified (2'-O-methyl/2'-MOE) to improve pharmacokinetics. The backbone is standard phosphate linkages.
|
| No information available. |
Summary of Clinical Use ![]() |
| Teprasiran was progressed as a clinical candidate. It was proposed to temporarily reduce p53 expression, and thereby limit p53-mediated acute kidney injury (induced by ischemia reperfusion injury) in high-risk patients undergoing cardiac surgery [2-3]. It was also evaluated for the prevention of delayed graft function in kidney transplants using organs from deceased donors. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02610296 | QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant | Phase 3 Interventional | Quark Pharmaceuticals | ||
| NCT00802347 | I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation | Phase 1/Phase 2 Interventional | Quark Pharmaceuticals | ||
| NCT03510897 | QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery | Phase 3 Interventional | Quark Pharmaceuticals | This study was terminated due to lack of efficacy in a predetermined 90 day treatment endpoint. | |
| NCT02610283 | A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery | Phase 2 Interventional | Quark Pharmaceuticals | ||